Laura Sepp-Lorenzino, Ph.D.

Laura Sepp-Lorenzino, Ph.D.

DirectoratIntellia Therapeutics· In proxies 2021–2025

Pay in FY2024+32% from the year before · Intellia Therapeutics stock -61.8% the same year

Laura Sepp-Lorenzino, Ph.D. was paid $5.5M in FY2024 (Dec), up 32%. Intellia Therapeutics stock fell 61.8% that year.

Pay$100 in the stock at the end of FY20 → $21
Pay is from the Summary Compensation Table of each Intellia Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Lexeo TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Taysha Gene TherapiesPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Intellia TherapeuticsPublic company · 5 yr
    • Executive Vice President, Chief Scientific Officer2021 – Present · 5 yrStock in role -79%
  4. Directors:Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards2

  • Taysha Gene TherapiesDirector · 5 yr on the boardIndependentAudit, Clinical and Scientific, Compensation—Paid as an executive
  • Lexeo TherapeuticsDirector · -1 yr on the boardIndependentScience and Technology—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?